Advanced Search

Technical Analysis for ARQT - Arcutis Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade A 29.7 8.59% 2.35
ARQT closed up 8.59 percent on Monday, March 30, 2020, on 20 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up
Historical ARQT trend table...
Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish 8.59%
Multiple of Ten Bearish Other 8.59%
Wide Bands Range Expansion 8.59%
Down 3 Days in a Row Weakness 8.59%
Down 4 Days in a Row Weakness 8.59%
Calm After Storm Range Contraction -4.19%
Narrow Range Bar Range Contraction -4.19%
Wide Bands Range Expansion -4.19%
Older EOD signals for ARQT ...
View Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
ARQT Chart by TradingView
Basic chart:

Profile

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Medical Specialties Immunology Organ Systems Autoimmune Diseases Psoriasis Atopic Dermatitis Dermatitis Eczema Atopy Dermatological Diseases Type I Hypersensitivity Vitiligo

Is ARQT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Mar 23 Kimberly Lathroum Joins Arcutis as Vice President of Marketing
Mar 23 105 Biggest Movers From Friday
Mar 16 Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis
Mar 13 Key events next week - healthcare
Mar 10 The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
Mar 5 Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications
Mar 5 Arcutis Biotherapeutics (ARQT) Presents At Cowen Health Care Conference - Slideshow
Mar 3 Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting
Feb 26 The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
Feb 23 The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
See more ARQT news...

Indicators

Indicator Value
52 Week High 40.88
52 Week Low 17.1
Average Volume 226,512
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 27.53
10-Day Moving Average 29.04
Average True Range 5.54
ADX 29.28
+DI 25.15
-DI 14.97
Chandelier Exit (Long, 3 ATRs ) 24.26
Chandelier Exit (Short, 3 ATRs ) 33.72
Upper Bollinger Band 37.93
Lower Bollinger Band 17.12
Percent B (%b) 0.6
BandWidth 75.61
MACD Line 1.35
MACD Signal Line 0.95
MACD Histogram 0.4036
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.01
Resistance 3 (R3) 37.12 33.46 36.63
Resistance 2 (R2) 33.46 31.34 33.91 36.16
Resistance 1 (R1) 31.58 30.04 32.52 32.47 35.70
Pivot Point 27.92 27.92 28.39 28.37 27.92
Support 1 (S1) 26.04 25.80 26.98 26.93 23.70
Support 2 (S2) 22.38 24.50 22.83 23.24
Support 3 (S3) 20.50 22.38 22.78
Support 4 (S4) 21.39